Sutro Biopharma (NASDAQ:STRO) Rating Lowered to “Underperform” at Bank of America
Bank of America cut shares of Sutro Biopharma (NASDAQ:STRO – Free Report) from a buy rating to an underperform rating in a research note issued to investors on Friday morning, Marketbeat reports. The brokerage currently has $1.00 target price on the stock, down from their prior target price of $11.00. STRO has been the topic […]
Bank of America cut shares of Sutro Biopharma (NASDAQ:STRO – Free Report) from a buy rating to an underperform rating in a research note issued to investors on Friday morning, Marketbeat reports. The brokerage currently has $1.00 target price on the stock, down from their prior target price of $11.00. STRO has been the topic […]
